SOURCE-LINKED STUDY SUMMARY
Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric Surgery.
Abstract summarizedQuality not appraised
- What was studied
- Retrospective comparison of prior GLP-1 medicine or tirzepatide use versus no prior use before bariatric surgery.
- Who / model studied
- 11,052 matched adults per group. Prior use meant a prescription 365 to 7 days before surgery; outcomes were tracked from postoperative day 1 through day 90.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Prior use was associated with fewer events in the primary combined cardiovascular outcome (0.3% versus 0.6%) and the key secondary kidney outcome (1.4% versus 2.3%). Coronary events and heart failure were also less frequent.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.amjmed.2026.09.010